Search Results
Jun 06, 2026, 09:07 ET People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
tirzepatide and supports patient goals for HbA1c and weight loss. By one year, both groups were associated with similar proportions of patients achieving an HbA1c of <7%, and people on semaglutide 2 mg had a statistically significant higher event rate for achieving weight loss ≥5% when
More news about: Novo Nordisk
Jun 06, 2026, 09:01 ET People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
tirzepatide and supports patient goals for HbA1c and weight loss. By one year, both groups were associated with similar proportions of patients achieving an HbA1c of <7%, and people on semaglutide 2 mg had a statistically significant higher event rate for achieving weight loss ≥5% when
More news about: Novo Nordisk
Jun 06, 2026, 09:00 ET Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes
regimens for future VESPER studies, including VESPER-4 phase 3 and VESPER-6 phase 3 studies.Trials Highlight Early Evidence of Injection for Combined Weight Loss and Blood Glucose Management BenefitsAdditionally, two additional studies presented demonstrating positive results for berobenatide.
More news about: American Diabetes Association
Jun 06, 2026, 09:00 ET New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
Kazemi, M.D., chief medical officer for Abbott's diabetes care business. "DKA remains one of the most preventable emergencies in diabetes care, yet too many people still miss early warning signs when ketones levels begin to rise. These findings underscore the need for better ways to recognize risk sooner
More news about: Abbott
Jun 06, 2026, 07:51 ET Chandigarh University holds 8th CU Online Annual Convocation; 363 Students Degrees Awarded
is going to create more and more opportunities all across the world for the learners who adapt and upskill themselves. The world is changing rapidly. If there has ever been a better time for learners in India to prepare themselves for the future, this is the time. I am pleased to see universities and
More news about: Chandigarh University
Jun 06, 2026, 06:11 ET Deepak Group Goes Beyond Green with hands-On Mangrove Restoration
Staying true to this year's theme 'Inspired by Nature. For Climate. For Our Future', this mangrove afforestation spread over 50-acres will be a sustained, community-anchored initiative that integrates local knowledge,
More news about: Deepak Nitrite Limited
Jun 06, 2026, 06:00 ET Leading Vision Insurance for Glasses (2026): VSP Individual Vision Plans Named Top Plan for Frames and Lens Coverage by Better Business Advice
eyewear needs, particularly for glasses. VSP Individual Vision Plans were noted for combining coverage for routine eye care with benefits designed to reduce the cost of frames and prescription lenses.Most plans include an annual eye exam after a copay, along with allowances for frames or contact lenses
More news about: BetterBusinessAdvice.com
Jun 06, 2026, 03:47 ET Shuja Rabbani Positions Human Resources as a Strategic Force for the GCC's Next Era of Business Transformation
Shuja Rabbani, a GCC-based HR practitioner, executive coach, speaker, and certified human capital leader whose work reflects the region's growing demand for future-ready people leadership. Following his completion of the Berkeley Transformative Chief Human Resources Officer Leadership Program, co-led
More news about: Shuja Rabbani
Jun 05, 2026, 23:06 ET CST Tires Showcases Lightweight Innovation at 2026 China International Bicycle Expo
and PortableFor the growing urban cycling market, CST Tires introduced tires catering to folding bikes for commuting and weekend "4+2" trips:CST CTC-39 ANCLA: Optimized for unpaved surfaces with polygonal central tread and herringbone pattern for stability, directional
More news about: CST Tires
Jun 05, 2026, 23:03 ET PICS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against PicS N.V. and Announces Opportunity for Investors with Substantial Losses to Lead the PicS N.V. Class Action Lawsuit
litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms
More news about: Robbins Geller Rudman & Dowd LLP
Jun 05, 2026, 22:12 ET NYT Investors Have the Opportunity to Join Investigation of The New York Times Company with the Schall Law Firm
NYT) for potential breaches of fiduciary duty on the part of its directors and management.
More news about: The Schall Law Firm
Jun 05, 2026, 22:00 ET SES AI Corporation Securities Fraud Class Action Result of Weak Revenue Guidance and 37% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
logistics constraints in Q4 2025 that materially impacted revenue for that quarter; (iv) these issues raised serious doubts about SES AI's 2026 growth prospects, which were later confirmed by weaker-than-expected revenue guidance for 2026; and (v) as a result, the Company's statements about its business,
More news about: Kahn Swick & Foti, LLC
Jun 05, 2026, 22:00 ET Sportradar Securities Fraud Class Action Result of Compliance Misrepresentations and 22% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
ordinary shares between November 7, 2024 and April 21, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.
More news about: Kahn Swick & Foti, LLC
Jun 05, 2026, 22:00 ET Roblox Investigation Initiated: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Roblox Corporation - RBLX
settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies.
More news about: Kahn Swick & Foti, LLC
Jun 05, 2026, 22:00 ET Lockheed Martin Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lockheed Martin Corporation - LMT
settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California,
More news about: Kahn Swick & Foti, LLC
Jun 05, 2026, 21:02 ET Think Together Awards 2026 Beyond Think Together Scholarships to Ten High School Seniors Across the State
solutions that change the odds for hundreds of thousands of California students each year. Think Education's program areas include early learning, afterschool programs, staffing, school improvement and leadership development for teachers and school administrators.For more information, call (888)
More news about: Think Together
Jun 05, 2026, 21:00 ET Tishman Speyer、APGおよびBouwinvestとのKorea Living Ventureで3億ドルの初回クロージングを達成
ンをもたらすことと整合している場合にのみ、長期的な成功と市場を上回る運用成果を達成できると認識しています。両者を統合することで、当社は社会に前向きな貢献をしながら、投資家の将来的な財務価値の保全と成長を両立させています。当社にとって、それこそが「生涯にわたる真の価値（real value for life）」です。写真 -
More news about: Tishman Speyer
Jun 05, 2026, 20:30 ET 46 Greenberg Traurig Attorneys Recognized in 2026 IAM Patent 1000
States for Prosecution and Trade Secret Litigation, Greenberg Traurig was recommended in the following key areas of practice in nine regions:California for LitigationColorado for ProsecutionIllinois for Prosecution and LitigationMassachusetts for Prosecution
More news about: Greenberg Traurig, LLP
Jun 05, 2026, 20:30 ET Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
activating RNA (saRNA) therapeutics, today announced that a late-breaking abstract on LiCO-saUcp1, its first-in-class saRNA candidate for obesity, has been accepted for poster presentation at the American Diabetes Association (ADA) 86th Scientific Sessions, being held June 5–8, 2026, in New Orleans, Louisiana.
More news about: Ractigen Therapeutics
Jun 05, 2026, 19:33 ET Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate
models underscores its differentiation and the potential of next-generation molecules for obesity and metabolic diseases," said Patrice Lee, Ph.D., President, R&D."Importantly, AMB-702 has the potential for lower effective human dosing, which we believe could substantially improve scalability.
More news about: Ambrosia Biosciences
Jun 05, 2026, 19:30 ET Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes
Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A novel electronic
More news about: American Diabetes Association
Jun 05, 2026, 19:30 ET Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026
glycemic efficacy, considering that the higher zenagamtide dose treatment groups were only exposed to the maintenance dose for a short period of time (ie 20 mg for 8 weeks and 40 mg for 4 weeks).1As a key supportive secondary endpoint, trial participants taking zenagamtide also saw a mean
More news about: NOVO NORDISK INC.
Jun 05, 2026, 19:30 ET Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial
disease who may remain at elevated risk for progression beyond what is fully captured by conventional renal biomarkers alone.CREDENCE was a landmark international renal outcomes trial that helped establish SGLT2 inhibitors as a foundational therapy for diabetic kidney disease. Despite major therapeutic
More news about: Precision Diabetes, Inc.
Jun 05, 2026, 19:25 ET Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/.FOR MORE INFORMATION:S&P Dow Jones
More news about: S&P Dow Jones Indices
Jun 05, 2026, 19:21 ET The City of Hallandale Beach Among 10 Finalists for Climate Protection from US Conference of Mayors; Cloud Receives Small City Award
sustainable transportation, and create meaningful benefits for residents while building a cleaner future for generations to come."Hallandale Beach was one of only five small cities in the nation who received the Honorable Mention Award for innovative energy and climate initiatives, a distinction
More news about: City of Hallandale Beach